As studies have shown that the gut incretin content is altered in animal models of type 2 diabetes [43], therefore AEATP may act by increasing incretin, that is, increasing glucagon-like-peptide-1 (GLP-1) or inhibiting dipeptidyl peptidase-4 (DPP-4). This evidence concerns the gene GCG and type 2 diabetes mellitus.